Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexatenaive patients with active rheumatoid arthritis: twentyfour-week results of a Phase III , multicenter, randomized, doubleblind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

December 2009
International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p130
Academic Journal
In this study, golimumab was found to be effective in a population of rheumatoid arthritis (RA) patients naïve to methotrexate therapy, although the combination of golimumab and methotrexate was not superior to methotrexate alone in terms of the primary endpoint, a 50% improvement in American College of Rheumatology criteria for RA (ACR50 response) at 24 weeks.


Related Articles

  • Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.  // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p132 

    Systematic reviews provide the best guidance for clinical practice. The present systematic review addressed the question of what is the best methotrexate dosing strategy and route of administration in patients with rheumatoid arthritis in terms of optimizing clinical and radiological response...

  • Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.  // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p134 

    In the management of early and established rheumatoid arthritis, methotrexate is recommended as a first-line drug by the European League Against Rheumatism and the American College of Rheumatology. The long-term safety of methotrexate, including issues of liver toxicity, hypersensitivity...

  • Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Tamborenea, Maria Natalia; Tate, Guillermo; Mysler, Eduardo; Debonis, Jose; Schijedman, Adrian // Rheumatology International;Mar2010, Vol. 30 Issue 5, p613 

    The main objective of this study is to determine the prevalence of positive and anergic tuberculin skin test (ppd) in a rheumatoid arthritis cohort of patients (RA) and assess the association among ppd results and clinical and treatment variables. Patients with RA diagnosis were included. The...

  • The Trends of DMARDS prescribed in Rheumatoid Arthritis Patients in Malaysia. Sulaiman, Wahinuddin; Toib, Ashraful; Chandrashehar, Giriyappanavar; Arshad, Anwar // Oman Medical Journal;Oct2009, Vol. 24 Issue 4, p260 

    Objectives: : To evaluate the trends of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis (RA). Methods: Patients who fulfilled the ACR criteria for RA from 1995 to 2006 and who attended the Rheumatology clinic at Ipoh Hospital were selected and their...

  • Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.  // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p130 

    Methotrexate polyglutamates are believed to represent the active form of the drug, and correlate with clinical response. This group studied 192 rheumatoid arthritis patients on chronic methotrexate therapy and observed that polyglutamate levels increased with age, methotrexate dose, and...

  • Long-term therapeutic effects and safety of tacrolimus added to methotrexate in patients with rheumatoid arthritis. Kanzaki, Takeyuki; Kawahata, Kimito; Kanda, Hiroko; Fujio, Keishi; Kubo, Kanae; Akahira, Lisa; Michishita, Kazuya; Eri, Toshiki; Yamamoto, Kazuhiko // Rheumatology International;Apr2013, Vol. 33 Issue 4, p871 

    To assess the long-term safety and efficacy of tacrolimus (TAC) used in combination with oral methotrexate (MTX) in patients with rheumatoid arthritis (RA) whose disease remains active despite treatment with MTX alone. The clinical courses of 24 RA patients who received TAC added to MTX from a...

  • Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. Antony, T.; Jose, V. M.; Paul, B. J.; Thomas, T. // Indian Journal of Medical Sciences;Aug2006, Vol. 60 Issue 8, p318 

    Background: Rheumatoid arthritis patients who develop refractoriness are left with no alternatives other than leflunomide and costly biological response modifiers. Leflunomide, though effective, was associated with adverse events and has not been extensively studied in the Indian...

  • PORTUGUESE GUIDELINES FOR THE USE OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS - MARCH 2010 UPDATE. Fonseca, João Eurico; Canhão, Helena; Reis, Paulo; Santos, Maria José; Branco, Jaime; Quintal, Alberto; Malcata, Armando; Araújo, Domingos; Ventura, Francisco; Figueiredo, Guilherme; da Silva, José Canas; Patto, José Vaz; de Queiroz, Mário Viana; Santos, Rui André; Neto, Adriano José Moreira; de Matos, Alves; Rodrigues, Ana; Mourão, Ana Filipa; Ribeiro, Ana Sofia Roxo; Cravo, Ana Rita // Acta Reumatológica Portuguesa;jan-mar2010, Vol. 35 Issue 1, p95 

    The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the...

  • Lederfolin.  // Royal Society of Medicine: Medicines;2002, p326 

    The article presents information on Lederfolin, is a proprietary, prescription-only preparation of calcium folinate, which can be used to counteract some of the toxic effects of certain anticancer drugs, especially methotrexate. It is available in a form for injection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics